NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $12.08 -0.06 (-0.49%) Closing price 04:00 PM EasternExtended Trading$12.07 -0.01 (-0.08%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nurix Therapeutics Stock (NASDAQ:NRIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nurix Therapeutics alerts:Sign Up Key Stats Today's Range$11.95▼$12.4750-Day Range$8.81▼$12.1552-Week Range$8.18▼$29.56Volume1.33 million shsAverage Volume880,750 shsMarket Capitalization$920.93 millionP/E RatioN/ADividend YieldN/APrice Target$30.44Consensus RatingModerate Buy Company OverviewNurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Read More… Nurix Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreNRIX MarketRank™: Nurix Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 668th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.84, and is based on 16 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageNurix Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nurix Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nurix Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.05% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 3.14%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.05% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 3.14%, indicating that investor sentiment is decreasing. News and Social Media3.4 / 5News Sentiment1.11 News SentimentNurix Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Nurix Therapeutics this week, compared to 6 articles on an average week.Search Interest3 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $221,500.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Nurix Therapeutics is held by insiders.Read more about Nurix Therapeutics' insider trading history. Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NRIX Stock News HeadlinesNurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $70,223.34 in StockMay 3, 2025 | insidertrades.comSanofi Exercises License Extension Option to Nurix’s STAT6 ProgramJune 3 at 2:59 AM | finance.yahoo.comThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind the scenes. An AI plan — authorized by Executive Order — is about to rewrite how the SSA operates.June 3, 2025 | Altimetry (Ad)Sanofi Exercises License Extension Option to Nurix's STAT6 ProgramJune 2 at 7:00 AM | globenewswire.comNurix Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comNurix Therapeutics reports stockholder voting resultsMay 21, 2025 | uk.investing.comNurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2025 | globenewswire.comNurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceMay 15, 2025 | globenewswire.comSee More Headlines NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $18.84 at the start of the year. Since then, NRIX shares have decreased by 35.9% and is now trading at $12.08. View the best growth stocks for 2025 here. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) posted its earnings results on Tuesday, April, 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. The business earned $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative trailing twelve-month return on equity of 53.65%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Top institutional investors of Nurix Therapeutics include Vanguard Group Inc. (5.79%), Redmile Group LLC (5.31%), Wellington Management Group LLP (4.18%) and T. Rowe Price Investment Management Inc. (3.19%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Stefani Wolff. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V). Company Calendar Last Earnings4/08/2025Today6/03/2025Next Earnings (Estimated)7/10/2025Fiscal Year End11/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRIX CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Target$30.44 High Stock Price Target$41.00 Low Stock Price Target$16.00 Potential Upside/Downside+152.0%Consensus RatingModerate Buy Rating Score (0-4)2.84 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$193.57 million Net Margins-354.85% Pretax Margin-354.36% Return on Equity-53.65% Return on Assets-38.59% Debt Debt-to-Equity RatioN/A Current Ratio6.46 Quick Ratio6.46 Sales & Book Value Annual Sales$56.42 million Price / Sales16.32 Cash FlowN/A Price / Cash FlowN/A Book Value$7.44 per share Price / Book1.62Miscellaneous Outstanding Shares76,236,000Free Float70,423,000Market Cap$920.93 million OptionableOptionable Beta2.23 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:NRIX) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.